Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Seliciclib |
Synonyms | |
Therapy Description |
Roscovotine (seliciclib) inhibits Cdc2, Cdk2 and Cdk5, which results in disruption of cell-cycle progression and decreased cell proliferation (PMID: 9030781, PMID: 9366565, PMID: 20822897) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Seliciclib | Roscovitine|CYC202 | CDK2 Inhibitor 31 CDK5 Inhibitor 8 | Roscovotine (seliciclib) inhibits Cdc2, Cdk2 and Cdk5, which results in disruption of cell-cycle progression and decreased cell proliferation (PMID: 9030781, PMID: 9366565, PMID: 20822897) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 wild-type | lung non-small cell carcinoma | sensitive | Seliciclib | Preclinical - Cell culture | Actionable | In a preclinical study, Roscovotine (seliciclib) induced substantial apoptosis in non-small cell lung carcinoma cells overexpressing wild-type TP53 in culture (PMID: 22862161). | 22862161 |
RB1 del SMARCB1 loss | rhabdoid cancer | sensitive | Seliciclib | Preclinical - Cell culture | Actionable | In a preclinical study, Roscovotine (seliciclib) inhibited viability of a SMARCB1-deficient rhabdoid cancer cell line with a deletion of RB1 in culture (PMID: 38315003). | 38315003 |
TP53 Y234C | lung non-small cell carcinoma | decreased response | Seliciclib | Preclinical - Cell culture | Actionable | In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 Y234C demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161). | 22862161 |
TP53 negative | lung non-small cell carcinoma | decreased response | Seliciclib | Preclinical - Cell culture | Actionable | In a preclinical study, TP53-null non-small cell lung carcinoma cells demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161). | 22862161 |
TP53 S215G | lung non-small cell carcinoma | resistant | Seliciclib | Preclinical - Cell culture | Actionable | In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 S215G were resistant to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161). | 22862161 |
TP53 Y220C | lung non-small cell carcinoma | resistant | Seliciclib | Preclinical - Cell culture | Actionable | In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 Y220C were resistant to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161). | 22862161 |
TP53 P98A | lung non-small cell carcinoma | decreased response | Seliciclib | Preclinical - Cell culture | Actionable | In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 P98A demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161). | 22862161 |
TP53 R175H | lung non-small cell carcinoma | resistant | Seliciclib | Preclinical - Cell culture | Actionable | In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 R175H were resistant to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161). | 22862161 |
TP53 A159V | lung non-small cell carcinoma | decreased response | Seliciclib | Preclinical - Cell culture | Actionable | In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 A159V demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161). | 22862161 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|